ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

NCT03732664 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

High-Risk Resectable NSCLC

Interventions

DRUG: Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University